Literature DB >> 15313161

A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype.

Akihiro Ishiguro1, Takahiro Kubota, Hiroshi Sasaki, Tatsuji Iga.   

Abstract

BACKGROUND: We found a genomic DNA (N=1) associated with an unidentified 11-kb EcoRI haplotype of CYP2D6 and with amplification of the CYP2D6*5 specific polymerase chain reaction (PCR) product without the 11.5-kb XbaI haplotype in a Japanese woman. We developed a long PCR assay to distinguish CYP2D6*5 and the novel mutant allele, and we evaluated the PCR method on 162 different genomic DNA samples.
METHODS: Long PCR assays were performed to amplify a fragment specific for the novel mutant allele and to exclude coamplification of CYP2D6*5.
RESULTS: A 1692-bp PCR product was amplified from the DNA sample with the novel mutant allele, while the PCR product was not amplified from any of the 162 DNA samples.
CONCLUSIONS: The long PCR assay enabled the detection of the novel mutant allele associated with an 11-kb EcoRI haplotype. Further population studies are required to confirm the frequency of the novel mutant allele in various populations, as it may be contained in samples reported as CYP2D6*5.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313161     DOI: 10.1016/j.cccn.2004.04.020

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 2.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane.

Authors:  Amity Peterson; Zuping Xia; Gang Chen; Philip Lazarus
Journal:  Pharmacol Res Perspect       Date:  2017-04-27

4.  A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.

Authors:  S Ryu; S Park; J H Lee; Y R Kim; H S Na; H S Lim; H Y Choi; I Y Hwang; J G Lee; Z W Park; W Y Oh; J M Kim; S E Choi
Journal:  Clin Transl Sci       Date:  2017-03-14       Impact factor: 4.689

5.  Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia.

Authors:  Wonsuk Shin; Minji Bang; Anhye Kim; Doo-Yeoun Cho; Sang-Hyuk Lee
Journal:  NPJ Schizophr       Date:  2021-01-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.